Edwards Lifesciences Q3 FY26: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 4, 2026
Revenue$1.72B
+10% year over year
Gross profit$1.35B
78% margin
Operating profit$0.30B
17% margin
Net profit$0.31B
18% margin
Net profit is larger than what operations earned, because the statement adds $0.07B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.72 | 100% | +10% |
| Aortic valve replacement | 1.24 | 72% | +8% |
| Surgical | 0.26 | 16% | |
| Transcatheter mitral | 0.21 | 12% | +44% |
| Cost of revenue | −0.37 | 22% | |
| Gross profit | 1.35 | 78% margin | +1pp |
| R&D | −0.28 | 16% | −2pp |
| SG&A | −0.56 | 33% | +0pp |
| Other | −0.21 | 12% | |
| Operating profit | 0.30 | 17% margin | −2pp |
| Other income, net | 0.07 | ||
| Tax | −0.06 | ||
| Net profit | 0.31 | 18% margin | −1pp |
11 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest